A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients: Difference between revisions
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Objective== To determine the safety, tolerability and pharmacokinetics of a single ascending dose of intravenous infusion of ..." |
|||
| Line 8: | Line 8: | ||
CSL-112 is a reconstituted formulation of apo A-1 derived from human plasma. This is a multi-center, randomized, double-blinded, placebo-controlled, single ascending dose study where the treatment group gets intravenous CSL-112. | CSL-112 is a reconstituted formulation of apo A-1 derived from human plasma. This is a multi-center, randomized, double-blinded, placebo-controlled, single ascending dose study where the treatment group gets intravenous CSL-112. | ||
==Results== | ==Results== | ||
Pending | |||
==Conclusion== | ==Conclusion== | ||
Revision as of 11:25, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients On the Web |
|
American Roentgen Ray Society Images of A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
To determine the safety, tolerability and pharmacokinetics of a single ascending dose of intravenous infusion of CSL-112 in patients with stable atherothrombotic disease.
Methods
CSL-112 is a reconstituted formulation of apo A-1 derived from human plasma. This is a multi-center, randomized, double-blinded, placebo-controlled, single ascending dose study where the treatment group gets intravenous CSL-112.
Results
Pending